Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 9/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15555052 | 0.85 | HTR2B (0.38) | HTR2BPARP1USP2 | |
| SCHEMBL1568072 | 0.77 | POLB (0.35) | — | |
| SCHEMBL1664728 | 0.76 | HTR2B (0.40) | HTR2BPARP1LMNAL3MBTL1 | |
| SCHEMBL13505317 | 0.73 | HCRTR1 (0.37) | — | |
| SCHEMBL2511920 | 0.72 | HTR2B (0.47) | HTR2BUSP2LMNAL3MBTL1 | |
| SCHEMBL4121296 | 0.71 | HTR2B (0.72) | HTR2B | |
| SCHEMBL7906028 | 0.70 | HTR2B (0.51) | HTR2BUSP2LMNA | |
| SCHEMBL27766579 | 0.70 | HTR2B (0.37) | HTR2BPARP1USP2L3MBTL1 | |
| SCHEMBL18150661 | 0.69 | HTR2B (0.34) | HTR2BPARP1 | |
| SCHEMBL16992222 | 0.68 | HTR2B (0.34) | HTR2BPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2491032-B1 | AKT INHIBITORS | LILLY CO ELI (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8436002-B2 | AKT inhibitors | ELI LILLY AND COMPANY (US) | 2013-05-07 | — | — | US | disclosed |
| EP-2491032-A1 | AKT INHIBITORS | Eli Lilly and Company (US) | 2012-08-29 | — | — | EP | disclosed |
| US-20120149684-A1 | AKT INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2011050016-A1 | AKT INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149684-A1 | AKT INHIBITORS | AKT2, PIK3CA, AKT3 | HTR2B 3577/4885PARP1 1626/4885USP2 3432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.